A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Study Summary

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.

Conditions

Lymphoblastic Lymphoma T-Cell Lymphoblastic Leukemia/Lymphoma Lymphoblastic Leukemia

Interventions / Drugs

BEAM-201

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment5 participants

Primary Completion—

Lead SponsorBeam Therapeutics Inc.

Data Retrieved2026-04-11 04:07:17.424736+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.